Needham Sees Buying Opportunity in This Penny Stock

GERN stock has more than doubled off its December lows

Apr 9, 2019 at 10:08 AM
facebook twitter linkedin

Geron Corporation (NASDAQ:GERN) stock is red-hot today, after Needham upgraded the cancer specialist to "buy" from "hold, and assigned a $3 price target -- a 63% premium to last night's close. The brokerage firm said the "negative optics of a big pharma passing on imetelstat" creates a buying opportunity for the penny stock. This comes after Johnson & Johnson (JNJ) subsidiary Janssen terminated its imetelstat collaboration with Geron last September.

In reaction, GERN stock is up 3.2% at $1.90, pacing toward its sixth straight win. Since bottoming below the $1 level in late December, the shares have more than doubled, but have struggled against the $2 mark -- near a massive Sept. 27 bear gap.

Analysts are optimistic, with all three in coverage maintaining a "buy" or better rating on GERN. Plus, the average 12-month price target sits all the way up at $3.63.

Short sellers, on the other hand, have heavily targeted GERN. The 41.09 million shares currently sold short represents 22% of the stock's available float, or 10.1 times the average daily pace of trading.


Minimize Risk While Maximizing Profits

There is no options strategy like this one, which consistently minimizes risk while maintaining maximum profits. Perfect for traders looking for ways to control risk, reduce losses, and increase the likelihood of success when trading calls and puts. The Schaeffer’s team has over 41 years of options trading success targeting +100% gains on every trade. Rest assured your losses are effectively limited to your initial cost at the time of making your move! Don't waste another second... join us right now before the next trade is released! 



Special Offers from Schaeffer's Trading Partners